Charcot neuro-osteoarthropathy (CNO) is a manifestation of peripheral neuropathy as a chronic complication of diabetes mellitus but, less frequently, can be associated to other conditions such as alcoholism or neurotoxic therapies. An increasingly emerging cause of CNO is the use of oncological drugs which can cause neuropathic damage. The use of these therapies dramatically increased in recent years. CNO leads to a progressive degeneration of the foot's joints and to bone destruction and resorption which ends in deformities. These alterations in the foot's anatomy determine a high risk of ulceration, infection, and osteomyelitis. The superimposition of osteomyelitis on CNO increases the risk of major amputation, already high in patients suffering either from only CNO or osteomyelitis alone. We report the case of a 61-year old nondiabetic woman affected by CNO as a consequence of antiblastic therapy for breast cancer and the subsequent overlap of osteomyelitis, confirmed by magnetic resonance imaging. This case underlines how it is necessary to consider CNO as a possible complication of antiblastic therapy in the view of the severe consequences of missing its diagnosis.

Download full-text PDF

Source
http://dx.doi.org/10.1177/15347346241254999DOI Listing

Publication Analysis

Top Keywords

charcot neuro-osteoarthropathy
8
antiblastic therapy
8
cno
7
osteomyelitis
5
neuro-osteoarthropathy superimposed
4
superimposed osteomyelitis
4
osteomyelitis nondiabetic
4
nondiabetic patient
4
patient consequence
4
consequence cancer
4

Similar Publications

To describe the demographic and clinical characteristics of patients with Charcot neuro-osteoarthropathy (CNO) and to examine for differences between participants with Type 1 diabetes mellitus (DM) (T1DM) and Type 2 diabetes mellitus (T2DM). Multicenter observational study in eight diabetic foot clinics in six countries between January 1, 1996, and December 31, 2022. Demographic, clinical, and laboratory parameters were obtained from the medical records.

View Article and Find Full Text PDF

Aim: Diabetic Charcot neuro-osteoarthropathy carries a significant worldwide disease burden including diabetic foot infection, ulceration and amputation. The current accepted standard of treatment during the active phase of Charcot neuro-osteoarthropathy is offloading with total contact casting; however, controversy remains regarding weight-bearing status during this period.

Methods: A systematic review was performed following PRISMA guidelines of Pubmed, EMBASE, MEDLINE and the Cochrane central register of controlled trials for clinical studies from inception until June 2024 investigating weight-bearing and non-weight-bearing total contact casting for active Charcot neuro-osteoarthropathy.

View Article and Find Full Text PDF
Article Synopsis
  • Charcot neuro-osteoarthropathy (CNO) primarily arises from diabetic neuropathy, leading to significant health complications and increasing healthcare demands worldwide.
  • Effective treatment requires a multi-disciplinary team due to the complex and varied nature of the disease, which complicates the creation of comprehensive treatment guidelines.
  • A literature review from 2003 to 2023 was conducted, resulting in an evidence-based algorithm to assist in surgical decision-making and enhance understanding of management strategies among the entire healthcare team.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!